Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q4 EPS of $0.18, $0.01 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $41.3 million versus the consensus estimate of $42.11 million.

Reaffirms FY12 outlook.

Earnings Guidance